Gujarat Themis Biosyn Ltd. Share Price & Stock Analysis

Gujarat Themis Biosyn Ltd. (BSE: 506879) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹5,051 Cr, it ranks #832 by market cap among the 6,197 Indian listed companies on FinBizNet, and #26 of 86 in Medicinal Chemicals and Botanical Products. At ₹389.00 (as of 16 Nov 2026), the share price is 17.2% below its 52-week high of ₹470.05 and 72.9% above its 52-week low of ₹225.05. The share price is down 13.7% over one year and up 11.9% over three months.

Key Metrics

Current Price₹389.00
Market Cap₹5,051 Cr
BSE Code506879
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Medicinal Chemicals and Botanical Products
P/E Ratio90.8
Return on Equity17.41%
Return on Assets9.74%
52-Week Range₹225.05 – ₹470.05
1-Year Price Change-13.7%
3-Month Price Change+11.9%
Beta (1Y)0.71
Dividend Yield0.17%
HeadquartersMumbai, Maharashtra
Websitewww.gtbl.in

Latest Quarterly Results — Q2 FY27

Revenue₹50 Cr
Net Profit₹-14 Cr
Net Margin-27.7%
EPS (Basic)₹-1.19
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Shareholding and Delivery

Promoters held 59.33% of Gujarat Themis Biosyn Ltd.'s shares as of Sept 2026, against 70.86% in Dec 2025 (−11.53 percentage points). Delivery averaged 50.5% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Gujarat Themis Biosyn Ltd.

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O for the treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.

Products and Services

1. Manufacturing Bulk Drugs-This segment manufactures bulk drugs.

Business Segments

1. Manufacturing Bulk Drugs-100%

Gujarat Themis Biosyn Ltd. vs Peers — Medicinal Chemicals and Botanical Products

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Sun Pharmaceutical Industries Limited₹4,56,425 Cr39.514.72%₹16,199 Cr+11.2%
Laurus Labs Ltd₹1,31,242 Cr145.617.74%₹2,206 Cr+146.8%
Zydus Lifesciences Ltd₹1,19,651 Cr24.118.32%₹7,910 Cr+26.0%
Dr.Reddys Lab₹1,15,464 Cr26.911.52%₹8,698 Cr+14.5%
Cipla Limited₹1,14,712 Cr29.311.74%₹7,404 Cr-7.6%
Mankind Pharma₹1,09,870 Cr5712.45%₹4,338 Cr+16.7%
Aurobindo Pharma Ltd.₹1,05,150 Cr309.93%₹10,263 Cr+59.8%
Lupin Ltd₹92,087 Cr17.326.91%₹7,827 Cr+0.4%
Gujarat Themis Biosyn Ltd.₹5,051 Cr90.817.41%₹50 Cr-13.7%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Gujarat Themis Biosyn Ltd.?

Gujarat Themis Biosyn Ltd. is trading at ₹389.00, with a market capitalisation of ₹5,051 Cr.

Which sector does Gujarat Themis Biosyn Ltd. belong to?

Gujarat Themis Biosyn Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).

What are the key financial ratios of Gujarat Themis Biosyn Ltd.?

Gujarat Themis Biosyn Ltd. has a P/E of 90.8 and a return on equity of 17.41%.

What is the stock symbol of Gujarat Themis Biosyn Ltd.?

Gujarat Themis Biosyn Ltd. is listed on the BSE under the scrip code 506879.

How has Gujarat Themis Biosyn Ltd.'s share price moved over the past year?

Gujarat Themis Biosyn Ltd.'s share price is down 13.7% over one year and up 11.9% over three months. Its 52-week range is ₹225.05 to ₹470.05.

What were Gujarat Themis Biosyn Ltd.'s latest quarterly results?

In Q2 FY27, Gujarat Themis Biosyn Ltd. reported revenue of ₹50 Cr and net profit of ₹-14 Cr, with basic EPS of ₹-1.19 (consolidated, parsed from the company's exchange filing).

What is the promoter holding in Gujarat Themis Biosyn Ltd.?

Promoters held 59.33% of Gujarat Themis Biosyn Ltd.'s shares as of Sept 2026, against 70.86% in Dec 2025 (−11.53 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.